Artificial intelligence for drug discovery.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Former Founders
Founder/CEO
Abraham Heifets is cofounder and CEO of Atomwise. He was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched compilers for high-performance data processing at IBM's T.J. Watson Research Center and helped build the AI system of the world-champion robotic soccer team at Cornell University. He was Time's Person of the Year in 2006.
Abraham Heifets is cofounder and CEO of Atomwise. He was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched compilers for high-performance data processing at IBM's T.J. Watson Research Center and helped build the AI system of the world-champion robotic soccer team at Cornell University. He was Time's Person of the Year in 2006.
Founder
Leveraging AI to revolutionize the physical sciences, Alex Levy is the CEO and co-founder of Atmo, the leading company integrating AI into global weather forecasting. Previously, he co-founded Atomwise (W15), a pioneering AI company in small molecule drug discovery, boasting over 800 active programs and $1 billion in pharmaceutical partnerships. An alumnus of the University of Toronto, he began his career by leading a computer vision research lab within the Computer Science Department.
Leveraging AI to revolutionize the physical sciences, Alex Levy is the CEO and co-founder of Atmo, the leading company integrating AI into global weather forecasting. Previously, he co-founded Atomwise (W15), a pioneering AI company in small molecule drug discovery, boasting over 800 active programs and $1 billion in pharmaceutical partnerships. An alumnus of the University of Toronto, he began his career by leading a computer vision research lab within the Computer Science Department.
